Health-related quality of life (HRQOL) is a comprehensive index to comprehensively assess the overall health status of patients in terms of physical, psychological, and social adjustment, and has been widely used in randomized controlled clinical trials and clinical work as an important observational index. We found that the application of the universal scale as a quality-of-life research tool in the study of specialist diseases has the potential for under-assessment. In order to investigate the sensitivity of the response of the specific and universal scales to the assessment of specialist diseases, we conducted the following study. We used the Bronchial Asthma Quality of Life Scale as a disease-specific scale and the SF36 scale as a universal scale to compare the difference in response sensitivity between the two in the assessment of bronchial asthma quality of life. Subjects and methods I. Subjects: Adult outpatients with asthma who met the diagnostic criteria for bronchial asthma established by the Chinese Medical Association in 2003 and who had an asthma attack or required bronchodilators in the last month. Except for the following patients: 1, chronic obstructive pulmonary disease; 2, occupational asthma; 3, critical asthma; 4, pregnant women; 5, combined with other diseases that may affect the quality of life. II. METHODS: 12-month non-double-blind fixed-group study to assess the quality of life of asthma patients at initial, 6 and 12 months using the Asthma Quality of Life Scale and the SF36 scale, respectively. 1, Quality of life scale. ① The 7-point adult asthma quality of life scale (7-AQLQ). There are 35 items in the scale, including 5 factors: activity limitation, asthma symptoms, reaction to irritants, mental-emotional, and self-health concern, and the lower the score, the worse the quality of life. ② 5-point Adult Asthma Quality of Life Scale (5-AQLQ), which has the same content as the 7-point scale, but is scored on a 5-point scale. ③ SF36. This scale is a disease-non-specific quality of life scale containing 36 entries with 8 dimensions, including physical function, role limitations (physical role limitations and emotional role limitations), social function, mental health, body pain, health cognition, health changes, and vitality, each containing 2 to 10 questions, and the sum of the 8 dimensional scores is the composite score. The higher the score, the higher the quality of life; we received permission from the authors to apply SF36. 2. Test items. Patients were tested on the 7-point and 5-point AQLQ and SF36 scales, respectively, at the initial visit, and then peak expiratory flow rate (PEF) was measured before and 20 minutes after inhalation of bronchodilators. Patients were retested after 6 and 12 months, respectively, using the three scales mentioned above, and PEF was also measured. During the observation period, PEF was measured daily in the morning and evening, and patients were asked to do the following when measuring PEF: 1) daily at PEF was measured daily at a fixed time such as 7:00 a.m. and 7:00 p.m. 2) The highest value of PEF was taken three times for each recording. 3) Bronchodilator aerosol was not inhaled 6 h before the daily measurement if possible. 4) PEF was measured standing up. Based on the PEF monitored each morning in the patient’s diary, the percentage of PEF to the expected value [6] was calculated, with PEF/pre ≥ 80% being mildly depressed and 60% ≤ PEF/pre